Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

Immunotherapy Spearheads Progress in Small Cell Lung Cancer

October 31st 2019

W. Victoria Lai, MD, discusses the impact immunotherapy has had in the management of patients with extensive-stage small cell lung cancer.

Osimertinib Continues to Flourish as Frontline Standard in EGFR-Mutant NSCLC

October 30th 2019

Khaled A. Hassan, MD, MS, discusses the use of EGFR TKIs in the treatment of patients with advanced EGFR-mutant non–small cell lung cancer and the emergence of osimertinib as the frontline standard of care.

Leveraging the Growing Arsenal of ALK and ROS1 Inhibitors in NSCLC

October 29th 2019

Nathan A. Pennell, MD, PhD, discusses the actionability of advanced ALK-positive and ROS1-positive non–small cell lung cancer and the drugs that have emerged in the frontline and second-line settings.

Former FDA Commissioner Scott Gottlieb Forecasts Future of Biosimilars

October 27th 2019

Scott Gottlieb, MD, discusses facets of biosimilar development as well as commercial and policy changes that could have the greatest impact on the use of these products in the field of oncology.

Surgeon Sheds Light on Early-Stage Interventions in Lung Cancer

October 25th 2019

Daniela Molena, MD, discusses the role of screening and the implementation of minimally invasive surgical techniques in early-stage lung cancer.

Overcoming Targeted Therapy Resistance in NSCLC

October 24th 2019

Timothy F. Burns, MD, PhD, discusses the frontline standards of care in EGFR-, ALK-, and ROS1-positive non–small cell lung cancer, optimal sequencing strategies, and the nuances of tissue- and plasma-based sequencing.

Coupling Novel Approaches With Chemo in Advanced Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses staples of treatment in metastatic prostate cancer as well as novel therapies and emerging strategies in the field.

Expert Hails NRG1 Fusions as the "Next Big Target" in Oncology

October 17th 2019

NRG1 fusions occur in low frequency across solid tumors, and because these alterations can evade traditional sequencing modalities, RNA-based next-generation sequencing is imperative.

Examining PD-L1 and TMB as Biomarkers of Immunotherapy Response in NSCLC

October 17th 2019

James G. Herman, MD, discusses the work that has been done to elucidate biomarkers of response to immunotherapy in non–small cell lung cancer and the necessity of molecular testing at diagnosis.

Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma

October 17th 2019

The addition of cisplatin to gemcitabine and nab-paclitaxel resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.

Tracing Treatment Strategies in Early-Stage HR+/HER2- Breast Cancer

October 16th 2019

Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.

Safety Analysis Supports Adjuvant T-DM1 Use in Early HER2+ Breast Cancer

October 14th 2019

Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.

Data Mine Demonstrates Heredity of Lung Cancers

October 12th 2019

Lisa A. Cannon-Albright, PhD, discusses her research regarding the heredity of lung cancer, histologic subgroups at increased risk, and the implications these data have on practice.

Biomarker Discovery Leads to Several Targeted Treatments in NSCLC

October 10th 2019

Wallace L. Akerley, MD, discusses targeted approaches for patients with non-small cell lung cancer who harbor alterations in MET, RET, and HER2, as well as the importance of broad molecular profiling.

Expert Sheds Light on Rapid Progress in Relapsed/Refractory Myeloma

October 8th 2019

Ivan M. Borrello, MD, discusses the most impactful agents that have entered the relapsed/refractory setting of multiple myeloma and details some of the guiding principles of treatment selection.

Improving CAR T-Cell Therapies With Greater Understanding of Cancer Immunology

October 8th 2019

Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.

PARP Inhibitors Continue to Flourish in Advanced Ovarian Cancer

October 7th 2019

Reagan M. Street, MD, MMS, discusses the shift toward targeted treatment in advanced ovarian cancer partly brought on by PARP inhibitors and the importance of hierarchical genomic testing.

FGFR2 Is Promising Second-Line Target in Cholangiocarcinoma

October 4th 2019

Treatment with pemigatinib resulted in a durable objective response rate in 35.5% of patients with previously treated, locally advanced or metastatic cholangiocarcinoma who harbored an FGFR2 fusion or rearrangement.

Targeted Agents Lead Treatment Advances in T-Cell Lymphoma

September 26th 2019

Jasmine M. Zain, MD, discusses the phase III ECHELON-2 trial and the ongoing work being done in peripheral T-cell lymphoma and other T-cell lymphomas.

Broader Trial Eligibility Criteria Expands Options for Brain Mets in Breast Cancer

September 26th 2019

Carey K. Anders, MD, discussed current approaches in the management of patients with breast cancer that has metastasized to the brain.